In conclusion, our data established that LY3009120, a selective panRAF inhibitor, is superior to previously investigated selective BRAF inhibition in preclinical models of human CRC, as it potently inhibited proliferation and tumor growth in the BRAFmut and KRASmut subtypes. Here, BRAF is linked to neoplasm.